Advertisement

Picture EBD Group BIO-Europe 2018 Copenhagen Denmark Partnerships 600x60px
Document › Details

Biodesix, Inc.. (1/26/17). "Press Release: Clin-TOF Successfully Integrated into VeriStrat Workflow. Study Results, Presented at MSACL, Advance Biodesix/Bioyong Agreement".

Region Region China
Organisations Organisation Biodesix Inc.
  Organisation 2 Bioyong Technology Co., Ltd.
Products Product VeriStrat® MS-based proteomic blood test
  Product 2 Clin-TOF MALDI mass spectrometry platform
Index term Index term Bioyong Technology–Biodesix: MS-based proteomic clinical test, 201701– collab $38m developm + marketing of VeriStrat test in Greater China by Bioyong
Person Person Ma, Qingwei (Bioyong Technology 201504 CEO + Founder)
     


Study results presented today demonstrate the feasibility of running the VeriStrat® test on Bioyong’s Clin-TOF platform, and provide a basis for validating and deploying a version of the VeriStrat® test in Greater China. The data were presented in a poster at the ninth annual conference of the Association for Mass Spectrometry: Applications to the Clinical Lab (MSACL) in Palm Springs, California.


Biodesix (Boulder, CO, USA) and Bioyong Technology Company Ltd. (Beijing, China) announced earlier this month that they have entered into an agreement whereby Bioyong will develop and commercialize a version of Biodesix’s VeriStrat® proteomic blood test for clinical use in Greater China, with potential expansion into other Asia-Pacific countries.

For the study, Bioyong’s Chinese FDA (CFDA)-cleared MALDI-TOF device was integrated into the VeriStrat® assay workflow. Biodesix used the same tiered qualification approach that it employs in its CLIA/CLEP-certified laboratory to analyze multiple sample sets with the Clin-TOF instrument. Across a total of 87 samples, concordance was 100%.

“The data from this study show that Bioyong’s Clin-TOF generates high-quality spectra and can support the VeriStrat® assay,” said Biodesix senior scientist Nicholas Dupuis, Ph.D. “Based on these results, we are confident of validating a version of the VeriStrat® test for the China market.”

“We are happy that our Clin-TOF platform has passed Biodesix’s strict qualification requirements,” said Dr. Ma, the founder and chairman of Bioyong. “This positive result gives us confidence that our plan to bring a version of the VeriStrat® test into clinical use in Greater China will be successful.”

With nearly 850,000 new lung cancer diagnoses predicted in 2020, China represent approximately 37% of new cases expected worldwide.


Poster title: Integration of the Clin-TOF into the VeriStrat® clinical testing workflow to generate serum protein profiles for prognosis and therapeutic guidance in NSCLC

Authors: Alex Nickel1, Qingwei Ma2, Maximillian Steers1, Nicholas F. Dupuis1 and Gary A. Pestano1

Institutions: 1. Biodesix, Inc. 2970 Wilderness Place, Boulder CO 80301, 2. Bioyong Technologies Co. Ltd., Beijing, China


Poster Presentation: January 26, 2017, 10:00AM; Poster #41D.

A copy of the poster can be accessed at: http://www.biodesix.com/wp-content/uploads/2017/01/MSACL_BDX-Bioyong_23Jan17.pdf


About the VeriStrat® test:

Biodesix’s VeriStrat® test is a predictive and prognostic blood-based proteomic test for patients with non-small cell lung cancer. The test is used to assess disease aggressiveness by characterizing host response to the tumor, classifying patients as either VeriStrat® Good or VeriStrat-Poor.


About Biodesix

Biodesix® is a molecular diagnostics company advancing the development of innovative blood tests in oncology to enable precision medicine. Biodesix discovers, develops and commercializes multivariate protein and genomic diagnostic blood tests, including the GeneStrat® and VeriStrat® tests, that deliver results within 72 hours. The company is changing the standard of care by providing physicians with diagnostic tests for better therapeutic guidance, more accurate prognosis and enhanced disease monitoring to improve patient outcomes. At the forefront of precision medicine, Biodesix is developing new blood tests to identify patients who may benefit from immunotherapies. In addition to developing novel diagnostics independently, the company partners with biotechnology and pharmaceutical companies to develop companion diagnostics for use with therapeutic agents.


About Bioyong

Bioyong Technology Company, Ltd has dedicated itself to developing mass spectrometry technologies for more than a decade. With the only/unique CFDA approval of domestic MALDI platform so far, Bioyong has expertise in serum peptidomics, nucleic acid detection and microorganism identifications. These technologies can and have been applied extensively in the growing field of precision medicine in an attempt to improve both diagnosis and prognosis for patients with a broad range of diseases. We are working hard to make the world healthier.

For more information about Bioyong, please visit www.bioyong.com.

   
Record changed: 2018-05-18

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany iito 600x60px

More documents for Biodesix Inc.


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture EBD Group BIO-Europe 2018 Copenhagen Denmark Partnering Open 600x60px




» top